Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Dividends Calendar
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team

Spago Nanomedical

0,2

 

SEK

 

-6,54 %

Mindre end 1K følgere

SPAGO

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Ownership
Investor consensus

Spago Nanomedical conducts research and development in cancer diagnostics. The company conducts various development projects based on its proprietary nanomaterials whose potential is found in making tumours visible, and enabling internal radiation therapy of cancer. The company was founded in 2007 and is based in Lund.

Læs mere
Markedsværdi
69,64 mio. SEK
Aktieomsætning
57,43 t SEK
Omsætning
1,91 mio.
EBIT %
-1.764,92 %
P/E
-
Udbytteafkast, %
-
Finanskalender
20.8
2025

Delårsrapport Q2'25

5.11
2025

Delårsrapport Q3'25

Alle
Selskabsmeddelelser
ViserAlle indholdstyper
Pressemeddelelse9.6.2025, 08.27

BioStock: Spago’s phase I/IIa cancer study on track for 2025 completion

Spago Nanomedical
Pressemeddelelse5.6.2025, 07.55

DNB Carnegie Access: Spago Nanomedical: Intervju - Närmar sig viktiga resultat

Spago Nanomedical
Pressemeddelelse3.6.2025, 10.04

DNB Carnegie Access: Spago Nanomedical: DMC gives green light to proceed

Spago Nanomedical

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Pressemeddelelse3.6.2025, 06.00

Spago Nanomedical continues patient recruitment in the phase I/IIa study Tumorad-01 as planned after DMC recommendation

Spago Nanomedical
Selskabsmeddelelse14.5.2025, 12.25

Bulletin from the 2025 Annual General Meeting of Spago Nanomedical AB

Spago Nanomedical
Pressemeddelelse8.5.2025, 13.52

Carnegie Access: Spago Nanomedical: Making steady progress in the Tumorad study – Q1(25) review

Spago Nanomedical
Selskabsmeddelelse7.5.2025, 06.00

Spago Nanomedical interim report January-March, 2025

Spago Nanomedical
Selskabsmeddelelse15.4.2025, 09.15

Spago Nanomedical publishes the annual report for 2024

Spago Nanomedical
Selskabsmeddelelse9.4.2025, 06.00

NOTICE TO ANNUAL GENERAL MEETING OF SPAGO NANOMEDICAL AB (PUBL)

Spago Nanomedical
Pressemeddelelse4.4.2025, 06.36

BioStock: Spago on the increased dose in Tumorad-01

Spago Nanomedical
Selskabsmeddelelse20.3.2025, 07.00

Nomination committee's proposal for a new chairman and composition of Spago Nanomedical’s board

Spago Nanomedical
Pressemeddelelse14.3.2025, 05.24

Carnegie Access: Spago Nanomedical: Highlights from Carnegie’s Healthcare Conference

Spago Nanomedical
Pressemeddelelse6.3.2025, 08.50

BioStock: Spago takes Tumorad-01 study to the next level

Spago Nanomedical
Pressemeddelelse4.3.2025, 11.54

Carnegie Access: Spago Nanomedical: Clears the next hurdle

Spago Nanomedical
Pressemeddelelse4.3.2025, 07.00

Spago Nanomedical proceeds with increased dose in the phase I/IIa study Tumorad-01

Spago Nanomedical
Pressemeddelelse10.2.2025, 15.08

Carnegie Access: Spago Nanomedical: Second cohort dosed and an update approaching

Spago Nanomedical
Selskabsmeddelelse6.2.2025, 07.00

Spago Nanomedical year-end report January-December, 2024

Spago Nanomedical
Pressemeddelelse15.1.2025, 07.30

Spago Nanomedical article on SPAGOPIX-01 clinical results accepted for publication in Investigative Radiology

Spago Nanomedical
Pressemeddelelse19.12.2024, 09.27

BioStock: Spago's CEO: "We want to expand cancer treatment with effective radiopharmaceuticals"

Spago Nanomedical
Pressemeddelelse18.12.2024, 07.00

Second patient group successfully dosed in Spago Nanomedical's Phase I/IIa study Tumorad-01

Spago Nanomedical
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.